Review



urinary bladder cancer cell line um uc 3  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 97
      Buy from Supplier

    Structured Review

    ATCC urinary bladder cancer cell line um uc 3
    Urinary Bladder Cancer Cell Line Um Uc 3, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 970 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/urinary+bladder+cancer+cell+line+um+uc+3/UM-UC-3/pm42032221-239-30-36
    Average 97 stars, based on 970 article reviews
    urinary bladder cancer cell line um uc 3 - by Bioz Stars, 2026-09
    97/100 stars

    Images

    Related Articles

    Multiple Displacement Amplification:

    Article Title: Automated microinjection for zebrafish xenograft models
    Article Snippet: For this study, we used the 2-day post fertilization (dpf) wild type ABTL, the transparent Casper, and the Tg(Fli: GFP) Casper zebrafish lines, the latter of which has GFP-expressing vasculature. .. A variety of substances were used for injections, including phenol red (Sigma-Aldrich, #114529), trypan blue (Thermo Fisher, #15250061), and red fluorescent dextran (Thermos fisher scientific, # D1818), the human muscle-invasive urinary bladder cancer cell line UM-UC-3 (ATCC, #CRL-1749), human tumor-infiltrating lymphocytes (TILs, purchased under a special partnership agreement from 4C Biomed), microspheres (Sigma-Aldrich, #L4530), breast cancer cell lines mCherry-labeled MDA-MB-231 (ATCC, HTB-26)), GFP-labeled MDA-MB-231(gently provided by Dr. Fernanda Raquel da Silva Andrade), mCherry labeled human prostate cancer cell lines PC3 (a kind gift from Dr. Maréne Landström), and GFP-labeled HCC1806 (gently provided by Dr. Fernanda Raquel da Silva Andrade), GFP-labeled glioma cells (SU-DIPG-XIIIp*, kindly provided by Dr. Sebastian Waszak), and clinical samples from bladder cancer patients. ..

    Article Title: Automated microinjection for zebrafish xenograft models
    Article Snippet: .. A variety of substances were used for injections, including phenol red (Sigma-Aldrich, #114529), trypan blue (Thermo Fisher, #15250061), and red fluorescent dextran (Thermos fisher scientific, # D1818), the human muscle-invasive urinary bladder cancer cell line UM-UC-3 (ATCC, #CRL-1749), human tumor-infiltrating lymphocytes (TILs, purchased under a special partnership agreement from 4C Biomed), microspheres (Sigma-Aldrich, #L4530), breast cancer cell lines mCherry-labeled MDA-MB-231 (ATCC, HTB-26)), GFP-labeled MDA-MB-231(gently provided by Dr. Fernanda Raquel da Silva Andrade), mCherry labeled human prostate cancer cell lines PC3 (a kind gift from Dr. Maréne Landström), and GFP-labeled HCC1806 (gently provided by Dr. Fernanda Raquel da Silva Andrade), GFP-labeled H3K27M-mutant diffuse midline glioma cells SU-DIPG-XIII-P* (the primary H3.3K27M-mutant cell line SU-DIPG-XIII-P* was obtained from Dr. Michelle Monje) , and clinical samples from bladder cancer patients. ..

    Article Title: Automated microinjection for zebrafish xenograft models.
    Article Snippet: .. A variety of substances were used for injections, including phenol red (Sigma-Aldrich, #114529), trypan blue (Thermo Fisher, #15250061), and red fluorescent dextran (Thermos fisher scientific, # D1818), the human muscle-invasive urinary bladder cancer cell line UM-UC-3 (ATCC, #CRL1749), human tumor-infiltrating lymphocytes (TILs, purchased under a special partnership agreement from 4C Biomed), microspheres (SigmaAldrich, #L4530), breast cancer cell lines mCherry-labeled MDA-MB-231 (ATCC, HTB-26)), GFP-labeled MDA-MB-231(gently provided by Dr. Fernanda Raquel da Silva Andrade), mCherry labeled human prostate cancer cell lines PC3 (a kind gift from Dr. Maréne Landström), and GFPlabeled HCC1806 (gently provided by Dr. Fernanda Raquel da Silva Andrade), GFP-labeled H3K27M-mutant diffuse midline glioma cells SUDIPG-XIII-P* (the primaryH3.3K27M-mutant cell line SU-DIPG-XIII-P* was obtained fromDr.MichelleMonje)52, and clinical samples frombladder cancer patients. ..

    Labeling:

    Article Title: Automated microinjection for zebrafish xenograft models
    Article Snippet: For this study, we used the 2-day post fertilization (dpf) wild type ABTL, the transparent Casper, and the Tg(Fli: GFP) Casper zebrafish lines, the latter of which has GFP-expressing vasculature. .. A variety of substances were used for injections, including phenol red (Sigma-Aldrich, #114529), trypan blue (Thermo Fisher, #15250061), and red fluorescent dextran (Thermos fisher scientific, # D1818), the human muscle-invasive urinary bladder cancer cell line UM-UC-3 (ATCC, #CRL-1749), human tumor-infiltrating lymphocytes (TILs, purchased under a special partnership agreement from 4C Biomed), microspheres (Sigma-Aldrich, #L4530), breast cancer cell lines mCherry-labeled MDA-MB-231 (ATCC, HTB-26)), GFP-labeled MDA-MB-231(gently provided by Dr. Fernanda Raquel da Silva Andrade), mCherry labeled human prostate cancer cell lines PC3 (a kind gift from Dr. Maréne Landström), and GFP-labeled HCC1806 (gently provided by Dr. Fernanda Raquel da Silva Andrade), GFP-labeled glioma cells (SU-DIPG-XIIIp*, kindly provided by Dr. Sebastian Waszak), and clinical samples from bladder cancer patients. ..

    Article Title: Automated microinjection for zebrafish xenograft models
    Article Snippet: .. A variety of substances were used for injections, including phenol red (Sigma-Aldrich, #114529), trypan blue (Thermo Fisher, #15250061), and red fluorescent dextran (Thermos fisher scientific, # D1818), the human muscle-invasive urinary bladder cancer cell line UM-UC-3 (ATCC, #CRL-1749), human tumor-infiltrating lymphocytes (TILs, purchased under a special partnership agreement from 4C Biomed), microspheres (Sigma-Aldrich, #L4530), breast cancer cell lines mCherry-labeled MDA-MB-231 (ATCC, HTB-26)), GFP-labeled MDA-MB-231(gently provided by Dr. Fernanda Raquel da Silva Andrade), mCherry labeled human prostate cancer cell lines PC3 (a kind gift from Dr. Maréne Landström), and GFP-labeled HCC1806 (gently provided by Dr. Fernanda Raquel da Silva Andrade), GFP-labeled H3K27M-mutant diffuse midline glioma cells SU-DIPG-XIII-P* (the primary H3.3K27M-mutant cell line SU-DIPG-XIII-P* was obtained from Dr. Michelle Monje) , and clinical samples from bladder cancer patients. ..

    Article Title: Automated microinjection for zebrafish xenograft models.
    Article Snippet: .. A variety of substances were used for injections, including phenol red (Sigma-Aldrich, #114529), trypan blue (Thermo Fisher, #15250061), and red fluorescent dextran (Thermos fisher scientific, # D1818), the human muscle-invasive urinary bladder cancer cell line UM-UC-3 (ATCC, #CRL1749), human tumor-infiltrating lymphocytes (TILs, purchased under a special partnership agreement from 4C Biomed), microspheres (SigmaAldrich, #L4530), breast cancer cell lines mCherry-labeled MDA-MB-231 (ATCC, HTB-26)), GFP-labeled MDA-MB-231(gently provided by Dr. Fernanda Raquel da Silva Andrade), mCherry labeled human prostate cancer cell lines PC3 (a kind gift from Dr. Maréne Landström), and GFPlabeled HCC1806 (gently provided by Dr. Fernanda Raquel da Silva Andrade), GFP-labeled H3K27M-mutant diffuse midline glioma cells SUDIPG-XIII-P* (the primaryH3.3K27M-mutant cell line SU-DIPG-XIII-P* was obtained fromDr.MichelleMonje)52, and clinical samples frombladder cancer patients. ..

    Cell Culture:

    Article Title: Novel Zebrafish Patient-Derived Tumor Xenograft Methodology for Evaluating Efficacy of Immune-Stimulating BCG Therapy in Urinary Bladder Cancer
    Article Snippet: .. The human muscle-invasive urinary bladder cancer cell line UM-UC-3 (ATCC, #CRL-1749) was cultured in T75-cell culture flasks in EMEM supplemented with 10% FBS and 1% Pen/Strep under standard cell culture conditions at 37 °C in a humidified incubator containing 5% CO 2 . ..



    Similar Products

    urinary bladder cancer cell line um uc 3  (ATCC)
    97
    ATCC urinary bladder cancer cell line um uc 3
    Urinary Bladder Cancer Cell Line Um Uc 3, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/urinary+bladder+cancer+cell+line+um+uc+3/UM-UC-3/pm42032221-239-30-36
    Average 97 stars, based on 1 article reviews
    urinary bladder cancer cell line um uc 3 - by Bioz Stars, 2026-09
    97/100 stars
    		  Buy from Supplier
    human urinary bladder cancer cell lines  (ATCC)
    97
    ATCC human urinary bladder cancer cell lines
    Human Urinary Bladder Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/urinary+bladder+cancer+cell+line+um+uc+3/UM-UC-3/pmc10775696-77-1-26
    Average 97 stars, based on 1 article reviews
    human urinary bladder cancer cell lines - by Bioz Stars, 2026-09
    97/100 stars
    		  Buy from Supplier
    t24 human urinary bladder cancer cell lines  (ATCC)
    97
    ATCC t24 human urinary bladder cancer cell lines
    A, Bdd does not trigger any innate immune response. No increase in the inflammatory cytokines concentrations was detected in the plasma of female BALB/cJ mice (n=3/group) 4 h after i.v. administration of the Bdd peptide (5 mg/kg, 150 μL). LPS was used as a positive control and concentrations of each cytokine were measured by ELISA kit. B, Cellular uptake of Cyanine5.5-labeled Bdd (Cy-Bdd). Representative fluorescence microscopic images of human UMUC-3 BC cells and murine Renca renal adenocarcinoma cells incubated for 6 and 24 h with Cy-Bdd (0.5 nmol). Dapi (9 μM) and LysoTracker-GFP (1 μM) were used for nuclear (blue) and organelle (green) staining, respectively, and were added to the cells 30 min prior to imaging. Scale bar is 25 μm. C, Comparing the potency of different chemotherapeutics (DM1, GEM, MIT, CIS, and DOX). UMUC-3 and Renca cells were incubated with the drugs at various concentrations for 72 h prior to measuring the cell viability. The dose response curves were plotted and the half maximal inhibitory concentrations (IC50 values) of each drug calculated using Graph Pad Prism 6.0 software. D, Conjugation of DM1 to Bdd. The cleavable linker SPDP was first conjugated to the peptide N-terminal in solid phase. DM1 was then added to the cleaved peptide in a solution mixture of PBS and NMP. E, Plot showing the percentage of accumulated DM1 released from the DM1-Bdd over time in PBS in the absence and presence of GSH (1 mM). The amount of drug released was quantified using rp-HPLC analysis (absorbance detected at 254 nm). F, Conjugation of aldox to Bdd. The peptide, supplemented with a N-terminal cysteine, was incubated with aldox in PBS (pH = 7.4) for 30 min prior to purification by rp-HPLC in neutral conditions. G, Plots showing the percentage of the accumulated DOX active metabolite released from aldox-Bdd (100 μM) over time in PBS buffers with different pH values. The amount of drug released was quantified using rp-HPLC analysis (absorbance detected at 480 nm). H, DM1-Bdd displays a similar cytotoxicity compared to free drug against murine bladder (MB49), human bladder (UMUC-3 and <t>T24),</t> and murine kidney (Renca) cancer cell lines. Plots of relative cell viability against the drug concentration. I, Aldox-Bdd is more potent than free aldox. Plots of the relative cell viability against the drug concentration.
    T24 Human Urinary Bladder Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/urinary+bladder+cancer+cell+line+um+uc+3/UM-UC-3/pmc08983499-136-2-26
    Average 97 stars, based on 1 article reviews
    t24 human urinary bladder cancer cell lines - by Bioz Stars, 2026-09
    97/100 stars
    		  Buy from Supplier
    human bladder cancer cell lines  (ATCC)
    94
    ATCC human bladder cancer cell lines
    A, Bdd does not trigger any innate immune response. No increase in the inflammatory cytokines concentrations was detected in the plasma of female BALB/cJ mice (n=3/group) 4 h after i.v. administration of the Bdd peptide (5 mg/kg, 150 μL). LPS was used as a positive control and concentrations of each cytokine were measured by ELISA kit. B, Cellular uptake of Cyanine5.5-labeled Bdd (Cy-Bdd). Representative fluorescence microscopic images of human UMUC-3 BC cells and murine Renca renal adenocarcinoma cells incubated for 6 and 24 h with Cy-Bdd (0.5 nmol). Dapi (9 μM) and LysoTracker-GFP (1 μM) were used for nuclear (blue) and organelle (green) staining, respectively, and were added to the cells 30 min prior to imaging. Scale bar is 25 μm. C, Comparing the potency of different chemotherapeutics (DM1, GEM, MIT, CIS, and DOX). UMUC-3 and Renca cells were incubated with the drugs at various concentrations for 72 h prior to measuring the cell viability. The dose response curves were plotted and the half maximal inhibitory concentrations (IC50 values) of each drug calculated using Graph Pad Prism 6.0 software. D, Conjugation of DM1 to Bdd. The cleavable linker SPDP was first conjugated to the peptide N-terminal in solid phase. DM1 was then added to the cleaved peptide in a solution mixture of PBS and NMP. E, Plot showing the percentage of accumulated DM1 released from the DM1-Bdd over time in PBS in the absence and presence of GSH (1 mM). The amount of drug released was quantified using rp-HPLC analysis (absorbance detected at 254 nm). F, Conjugation of aldox to Bdd. The peptide, supplemented with a N-terminal cysteine, was incubated with aldox in PBS (pH = 7.4) for 30 min prior to purification by rp-HPLC in neutral conditions. G, Plots showing the percentage of the accumulated DOX active metabolite released from aldox-Bdd (100 μM) over time in PBS buffers with different pH values. The amount of drug released was quantified using rp-HPLC analysis (absorbance detected at 480 nm). H, DM1-Bdd displays a similar cytotoxicity compared to free drug against murine bladder (MB49), human bladder (UMUC-3 and <t>T24),</t> and murine kidney (Renca) cancer cell lines. Plots of relative cell viability against the drug concentration. I, Aldox-Bdd is more potent than free aldox. Plots of the relative cell viability against the drug concentration.
    Human Bladder Cancer Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/urinary+bladder+cancer+cell+line+um+uc+3/UM-UC-3%3B+Urinary+Bladder+Cancer%3B+Human/pm34057764-73-1-16
    Average 94 stars, based on 1 article reviews
    human bladder cancer cell lines - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier
    human urinary bladder carcinoma cell lines  (ATCC)
    94
    ATCC human urinary bladder carcinoma cell lines
    A, Bdd does not trigger any innate immune response. No increase in the inflammatory cytokines concentrations was detected in the plasma of female BALB/cJ mice (n=3/group) 4 h after i.v. administration of the Bdd peptide (5 mg/kg, 150 μL). LPS was used as a positive control and concentrations of each cytokine were measured by ELISA kit. B, Cellular uptake of Cyanine5.5-labeled Bdd (Cy-Bdd). Representative fluorescence microscopic images of human UMUC-3 BC cells and murine Renca renal adenocarcinoma cells incubated for 6 and 24 h with Cy-Bdd (0.5 nmol). Dapi (9 μM) and LysoTracker-GFP (1 μM) were used for nuclear (blue) and organelle (green) staining, respectively, and were added to the cells 30 min prior to imaging. Scale bar is 25 μm. C, Comparing the potency of different chemotherapeutics (DM1, GEM, MIT, CIS, and DOX). UMUC-3 and Renca cells were incubated with the drugs at various concentrations for 72 h prior to measuring the cell viability. The dose response curves were plotted and the half maximal inhibitory concentrations (IC50 values) of each drug calculated using Graph Pad Prism 6.0 software. D, Conjugation of DM1 to Bdd. The cleavable linker SPDP was first conjugated to the peptide N-terminal in solid phase. DM1 was then added to the cleaved peptide in a solution mixture of PBS and NMP. E, Plot showing the percentage of accumulated DM1 released from the DM1-Bdd over time in PBS in the absence and presence of GSH (1 mM). The amount of drug released was quantified using rp-HPLC analysis (absorbance detected at 254 nm). F, Conjugation of aldox to Bdd. The peptide, supplemented with a N-terminal cysteine, was incubated with aldox in PBS (pH = 7.4) for 30 min prior to purification by rp-HPLC in neutral conditions. G, Plots showing the percentage of the accumulated DOX active metabolite released from aldox-Bdd (100 μM) over time in PBS buffers with different pH values. The amount of drug released was quantified using rp-HPLC analysis (absorbance detected at 480 nm). H, DM1-Bdd displays a similar cytotoxicity compared to free drug against murine bladder (MB49), human bladder (UMUC-3 and <t>T24),</t> and murine kidney (Renca) cancer cell lines. Plots of relative cell viability against the drug concentration. I, Aldox-Bdd is more potent than free aldox. Plots of the relative cell viability against the drug concentration.
    Human Urinary Bladder Carcinoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/urinary+bladder+cancer+cell+line+um+uc+3/UM-UC-3%3B+Urinary+Bladder+Cancer%3B+Human/pm33176187-76-0-7
    Average 94 stars, based on 1 article reviews
    human urinary bladder carcinoma cell lines - by Bioz Stars, 2026-09
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    A, Bdd does not trigger any innate immune response. No increase in the inflammatory cytokines concentrations was detected in the plasma of female BALB/cJ mice (n=3/group) 4 h after i.v. administration of the Bdd peptide (5 mg/kg, 150 μL). LPS was used as a positive control and concentrations of each cytokine were measured by ELISA kit. B, Cellular uptake of Cyanine5.5-labeled Bdd (Cy-Bdd). Representative fluorescence microscopic images of human UMUC-3 BC cells and murine Renca renal adenocarcinoma cells incubated for 6 and 24 h with Cy-Bdd (0.5 nmol). Dapi (9 μM) and LysoTracker-GFP (1 μM) were used for nuclear (blue) and organelle (green) staining, respectively, and were added to the cells 30 min prior to imaging. Scale bar is 25 μm. C, Comparing the potency of different chemotherapeutics (DM1, GEM, MIT, CIS, and DOX). UMUC-3 and Renca cells were incubated with the drugs at various concentrations for 72 h prior to measuring the cell viability. The dose response curves were plotted and the half maximal inhibitory concentrations (IC50 values) of each drug calculated using Graph Pad Prism 6.0 software. D, Conjugation of DM1 to Bdd. The cleavable linker SPDP was first conjugated to the peptide N-terminal in solid phase. DM1 was then added to the cleaved peptide in a solution mixture of PBS and NMP. E, Plot showing the percentage of accumulated DM1 released from the DM1-Bdd over time in PBS in the absence and presence of GSH (1 mM). The amount of drug released was quantified using rp-HPLC analysis (absorbance detected at 254 nm). F, Conjugation of aldox to Bdd. The peptide, supplemented with a N-terminal cysteine, was incubated with aldox in PBS (pH = 7.4) for 30 min prior to purification by rp-HPLC in neutral conditions. G, Plots showing the percentage of the accumulated DOX active metabolite released from aldox-Bdd (100 μM) over time in PBS buffers with different pH values. The amount of drug released was quantified using rp-HPLC analysis (absorbance detected at 480 nm). H, DM1-Bdd displays a similar cytotoxicity compared to free drug against murine bladder (MB49), human bladder (UMUC-3 and T24), and murine kidney (Renca) cancer cell lines. Plots of relative cell viability against the drug concentration. I, Aldox-Bdd is more potent than free aldox. Plots of the relative cell viability against the drug concentration.

    Journal: Cancer research

    Article Title: A urinary drug-disposing approach as an alternative to intravesical chemotherapy for treating non-muscle invasive bladder cancer

    doi: 10.1158/0008-5472.CAN-21-2897

    Figure Lengend Snippet: A, Bdd does not trigger any innate immune response. No increase in the inflammatory cytokines concentrations was detected in the plasma of female BALB/cJ mice (n=3/group) 4 h after i.v. administration of the Bdd peptide (5 mg/kg, 150 μL). LPS was used as a positive control and concentrations of each cytokine were measured by ELISA kit. B, Cellular uptake of Cyanine5.5-labeled Bdd (Cy-Bdd). Representative fluorescence microscopic images of human UMUC-3 BC cells and murine Renca renal adenocarcinoma cells incubated for 6 and 24 h with Cy-Bdd (0.5 nmol). Dapi (9 μM) and LysoTracker-GFP (1 μM) were used for nuclear (blue) and organelle (green) staining, respectively, and were added to the cells 30 min prior to imaging. Scale bar is 25 μm. C, Comparing the potency of different chemotherapeutics (DM1, GEM, MIT, CIS, and DOX). UMUC-3 and Renca cells were incubated with the drugs at various concentrations for 72 h prior to measuring the cell viability. The dose response curves were plotted and the half maximal inhibitory concentrations (IC50 values) of each drug calculated using Graph Pad Prism 6.0 software. D, Conjugation of DM1 to Bdd. The cleavable linker SPDP was first conjugated to the peptide N-terminal in solid phase. DM1 was then added to the cleaved peptide in a solution mixture of PBS and NMP. E, Plot showing the percentage of accumulated DM1 released from the DM1-Bdd over time in PBS in the absence and presence of GSH (1 mM). The amount of drug released was quantified using rp-HPLC analysis (absorbance detected at 254 nm). F, Conjugation of aldox to Bdd. The peptide, supplemented with a N-terminal cysteine, was incubated with aldox in PBS (pH = 7.4) for 30 min prior to purification by rp-HPLC in neutral conditions. G, Plots showing the percentage of the accumulated DOX active metabolite released from aldox-Bdd (100 μM) over time in PBS buffers with different pH values. The amount of drug released was quantified using rp-HPLC analysis (absorbance detected at 480 nm). H, DM1-Bdd displays a similar cytotoxicity compared to free drug against murine bladder (MB49), human bladder (UMUC-3 and T24), and murine kidney (Renca) cancer cell lines. Plots of relative cell viability against the drug concentration. I, Aldox-Bdd is more potent than free aldox. Plots of the relative cell viability against the drug concentration.

    Article Snippet: UMUC-3 and T24 human urinary bladder cancer cell lines (Cat# CRL-1749 and Cat# HTB-4), and Renca murine kidney adenocarcinoma cell line (Cat# CRL-2947), were obtained from ATCC (Manassas, VA).

    Techniques: Clinical Proteomics, Positive Control, Enzyme-linked Immunosorbent Assay, Labeling, Fluorescence, Incubation, Staining, Imaging, Software, Conjugation Assay, Purification, Concentration Assay